Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa

Krystal Biotech, Inc. announced the submission of a Biologics License Application FDA seeking approval of B-VEC for the treatment of patients with dystrophic epidermolysis bullosa.